{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:35:26Z","timestamp":1788824126574,"version":"build-2803163510"},"reference-count":16,"publisher":"Georg Thieme Verlag KG","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n          Background Topical NGF eye drops (Cenegermin) were approved in 2015 as an orphan drug for the treatment of neurotrophic keratopathy (NK). The active substance Cenegermin is a recombinant form of human NGF (nerve growth factor).<\/jats:p><jats:p>\n          Objectives Presentation of efficacy and safety of Cenegermin for use in patients in an university real-life setting.<\/jats:p><jats:p>\n          Material and Methods Retrospective study at the K\u00f6ln University Eye Hospital from 2017 to 2019 with n\u2009=\u200911 eyes. Average follow-up was 13.5\u2009\u00b1\u20097.1 months. Reasons for treatment were neurotrophic keratopathy stage II and III, clinically mostly in combination with corneal neovascularization.<\/jats:p><jats:p>\n          Results Seven eyes with a NK II and 4 eyes with a NK III with a median observation period of 13.6 months (range 1.2\u200a\u2013\u200a20.3 months) from a total of 11 patients were included. The median patient age was 42.8\u2009\u00b1\u200923.6 years (range 18\u200a\u2013\u200a75 years). Before the start of therapy, the median erosion area measured 3.1\u2009\u00b1\u20091.4\u2009\u00d7\u20091.9\u2009\u00b1\u20091.1\u2009mm and the median ulcer area had a size of 2.3\u2009\u00b1\u20091.1\u2009\u00d7\u20092.1\u2009\u00b1\u20090.8\u2009mm. After the start of therapy with Cenegermin (application 6\u00d7\/day), the epithelial defect closed in all 11 study eyes (100%) within 4\u200a\u2013\u200a12 weeks (mean: 49\u2009d\u2009\u00b1\u20099\u2009d). In 9 out of 10 patients (90%) pre-existing corneal neovascularization regressed significantly (p\u2009&lt;\u20090.001). Before the start of therapy, a value in the Luneau test of 2.9\u2009\u00b1\u20091.9 (minimum 1\/6, maximum 4\/6) was found and rose to a median value of 4.2\u2009\u00b1\u20091.7 (minimum 2\/6, maximum 6\/6) after 18 months (p\u2009=\u20090.015). Therapy with Cenegermin had no long-term effect on intraocular pressure: the pressure ranged between\n\t\t\t\t\t13.2\u2009\u00b1\u20094.1\u2009mmHg (minimum 8\u2009mmHg, maximum 21\u2009mmHg). Under therapy with NGF eye drops, 67% of the patients, after an initial decrease, showed a long-term improvement in visual acuity (BSCVA) from 0.72\u2009\u00b1\u20090.31 to 0.46\u2009\u00b1\u20090.29 logMAR after 18 months (p\u2009=\u20090.005). Relapses in form of a corneal erosion in the long-term follow-up were observed in only one eye. One patient had to stop therapy because of local pain, no other local and systemic side effects were observed.<\/jats:p><jats:p>\n          Conclusion This real-life series on the use of Cenegermin in a university context shows a good effectiveness of the substance for epithelial closure in various underlying diseases (100% within 12 weeks). There is a long-term improvement in vision and corneal sensitivity. Larger real-life cohorts with various underlying diseases should follow.<\/jats:p>","DOI":"10.1055\/a-1274-3675","type":"journal-article","created":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T23:41:23Z","timestamp":1607384483000},"page":"1455-1461","source":"Crossref","is-referenced-by-count":14,"title":["Real Life Data on Efficacy and Safety of Topical NGF Eye Drops (Cenegermin)"],"prefix":"10.1055","volume":"237","author":[{"given":"Sarah Barbara","family":"Zwingelberg","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum K\u00f6ln, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn O.","family":"Bachmann","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum K\u00f6ln, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Cursiefen","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Augenheilkunde, Universit\u00e4tsklinikum K\u00f6ln, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2020,12,7]]},"reference":[{"key":"ref3","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1097\/ICO.0000000000000250","article-title":"Corneal nerve alterations after Descemet membrane endothelial keratoplasty: an in vivo confocal microscopy study","volume":"33","author":"F Bucher","year":"2014","journal-title":"Cornea"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/13543784.2019.1677605","article-title":"Recent innovations with drugs in clinical trials for neutrotrophic keratitis and refractory corneal ulcers","volume":"28","author":"D Bremond-Gignac","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2147\/OPTH.S185184","article-title":"Update on Cenegermin eye drops in the treatment of neurotrophic keratitis","volume":"13","author":"H Sheha","year":"2019","journal-title":"Clin Ophthalmol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00347-018-0843-5","article-title":"Aktuelle und experimentelle Therapieans\u00e4tze bei neutrotropher Keratopathie","volume":"116","author":"J Adler","year":"2019","journal-title":"Ophthalmologe"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00347-004-1140-z","article-title":"Neurotrophic keratitis","volume":"102","author":"C Cursiefen","year":"2005","journal-title":"Ophthalmologe"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","article-title":"Neurotrophic keratopathy","volume":"66","author":"H S Dua","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"ref9","first-page":"15","article-title":"[Conservative and surgical treatment of neurotrophic keratopathy]","volume":"102","author":"B Seitz","year":"2005","journal-title":"Ophthalmologe"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","article-title":"Topical recombinant human nerve growth factor (Cenegermin) for neutrotrophic keratopathy","volume":"127","author":"S C Pflugfelder","year":"2020","journal-title":"Ophthalmology"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s41669-019-0138-z","article-title":"Cenegermin for treating neutrophic keratitis: An evidence review group perspective of a NICE single technology appraisal","volume":"3","author":"N Fleeman","year":"2019","journal-title":"Pharmacoecon Open"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ophtha.2009.04.016","article-title":"GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization","volume":"116","author":"C Cursiefen","year":"2009","journal-title":"Ophthalmology"},{"key":"ref14","first-page":"1036","article-title":"[Manufacture of autologous serum eye drops for out-patient therapy: cooperation between ophthalmic clinic and transfusion medicine department]","volume":"105","author":"T Dietrich","year":"2008","journal-title":"Ophthalmologe"},{"key":"ref15","first-page":"322","article-title":"Treatment of severe chronic ocular graft-versus-host disease using 100\u200a% autologous serum eye drops from a sealed manufacturing system: a retrospective cohort study","volume":"101","author":"V Tahmaz","year":"2017","journal-title":"Br J Ophthalmol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","article-title":"Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"S Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","article-title":"Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis","volume":"125","author":"S Bonini","year":"2018","journal-title":"Ophthalmology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40265-020-01289-w","article-title":"Cenegermin: a review in neutrotrophic keratitis","volume":"80","author":"E D Deecks","year":"2020","journal-title":"Drugs"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1097\/ICO.0000000000002300","article-title":"Epithelial plaque formation secondary to recombinant human nerve growth factor","volume":"39","author":"E Weinlander","year":"2020","journal-title":"Cornea"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1274-3675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T23:41:55Z","timestamp":1607384515000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1274-3675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":16,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2020,12,7]]},"published-print":{"date-parts":[[2020,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1274-3675","relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12]]}}}